Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finafloxacin - MerLion Pharmaceuticals

Drug Profile

Finafloxacin - MerLion Pharmaceuticals

Alternative Names: AL-60371; BY-377; EXE 844; EXE 844b; Finafloxacin hydrochloride; Gastrochinolon; Gastroquinolone; Xtoro

Latest Information Update: 28 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer Alcon; MerLion Pharmaceuticals
  • Class Antibacterials; Eye disorder therapies; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Otitis externa
  • Phase II Helicobacter infections; Pyelonephritis; Urinary tract infections
  • No development reported Bacterial infections; Otitis media; Respiratory tract infections

Most Recent Events

  • 28 Dec 2018 No recent reports of development identified for phase-I development in Otitis-media(In children, In infants) in USA (Otic, Suspension)
  • 31 Jul 2018 MerLion regains global rights to finafloxacin after termination of licensing deal between Alcon and MerLion
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in United Kingdom (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top